Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

OBJECTIVE: To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID) in patients with multiple sclerosis (MS). MET...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neurology
Hlavní autoři: Ryerson, Lana Zhovtis, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan R., Goldberg, Judith D., Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Kasliwal, Rachna, Ren, Zheng, Hotermans, Christophe, Ho, Pei-Ran, Campbell, Nolan
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7010325/
https://ncbi.nlm.nih.gov/pubmed/31515290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000008243
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky